Sangamo Therap
SGMO0.07400.00% ( 0.0000 )
Sangamo Therap (SGMO)
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and fa...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- 0.0740
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- 0.7660
- Volume Ratio
- 0.00
- Turnover Ratio
- --
Sangamo Therap Analyst Rating
View MoreForecast & Rating
Jun 9, 2026Price forecast
$1.672152.26%
Forecast & RatingBuy
3analysts
- Strong buy33.33%
- Buy0.00%
- Hold66.67%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 20 at 03:45 PM
Sangamo loses Nasdaq listing appeal after minimum bid price breach
- biopharmadive · Jun 24 at 09:32 AM
Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor
- PUBT · Jun 23 at 03:42 PM
Sangamo amends 8-K to file asset purchase agreement exhibits
- benzinga_article · Jun 23 at 12:46 PM
Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circle
- TradingView · Jun 23 at 07:53 AM
Sangamo Therapeutics Sets Stalking Horse Sales: $50M to Eli Lilly, Up to $50M to Astellas
- PUBT · Jun 23 at 07:47 AM
Sangamo lines up up to $30 million debtor-in-possession loan from Northridge ATM amid Chapter 11 filing
